Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | TACR1 | P25103 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10210891 | 0.84 | MEN1 (0.56) | MAPK1SMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL6483885 | 0.81 | MAPK1 (0.48) | MAPK1SMN1; SMN2MEN1KMT2ATACR1 | |
| SCHEMBL2094838 | 0.80 | KDM4E (0.66) | SMN1; SMN2MEN1KMT2AKDM4EPOLB | |
| SCHEMBL4185685 | 0.79 | TACR1 (0.61) | MAPK1SMN1; SMN2MEN1KMT2ATACR1 | |
| SCHEMBL4187783 | 0.78 | MEN1 (0.48) | MAPK1SMN1; SMN2MEN1KMT2ATACR1 | |
| SCHEMBL21651001 | 0.77 | POLB (0.57) | MAPK1SMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL5709517 | 0.77 | MAPK1 (0.48) | MAPK1SMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL13100266 | 0.76 | CACNA1B (0.54) | MAPK1SMN1; SMN2MEN1KMT2ATACR1 | |
| SCHEMBL4181293 | 0.76 | CXCR4 (0.50) | MAPK1SMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL13627363 | 0.76 | POLB (0.47) | MAPK1SMN1; SMN2MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6969712-B2 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-29 | — | — | US | disclosed |
| US-20040044056-A1 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-04 | — | — | US | disclosed |
| EP-1342717-A1 | BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044056-A1 | Benzimidazole derivatives | GPR119, OPRL1, INSR | MAPK1 2174/4885SMN1; SMN2 1869/4885MEN1 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.